Evolution Advisers Inc. Has $52,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Evolution Advisers Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 212.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 294 shares of the company’s stock after purchasing an additional 200 shares during the quarter. Evolution Advisers Inc.’s holdings in Johnson & Johnson were worth $52,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of JNJ. Patron Partners LLC boosted its stake in Johnson & Johnson by 12.7% in the first quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock valued at $1,174,000 after buying an additional 747 shares in the last quarter. Tandem Investment Advisors Inc. raised its position in Johnson & Johnson by 4.8% in the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after purchasing an additional 15,003 shares during the last quarter. Argent Advisors Inc. raised its position in Johnson & Johnson by 6.6% in the first quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock valued at $3,504,000 after purchasing an additional 1,218 shares during the last quarter. Exeter Financial LLC raised its position in Johnson & Johnson by 3.2% in the first quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock valued at $4,684,000 after purchasing an additional 819 shares during the last quarter. Finally, Fusion Capital LLC raised its position in Johnson & Johnson by 7.8% in the first quarter. Fusion Capital LLC now owns 27,844 shares of the company’s stock valued at $4,935,000 after purchasing an additional 2,019 shares during the last quarter. 68.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Wells Fargo & Company raised their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. The Goldman Sachs Group raised their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Daiwa Capital Markets began coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating for the company. Finally, UBS Group lowered their price objective on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Stock Down 0.4 %

Shares of NYSE:JNJ opened at $171.11 on Friday. The stock has a market cap of $449.88 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 3.32 and a beta of 0.59. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The business’s 50 day moving average is $175.21 and its 200 day moving average is $174.55.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. Johnson & Johnson’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.48 earnings per share. On average, sell-side analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.64%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.